Cargando…

Dose optimization of brodalumab in moderate-to-severe plaque psoriasis: A case report

Brodalumab, a monoclonal antibody that targets the interleukin-17 receptor, is a new treatment option for moderate-to-severe plaque psoriasis with a unique mechanism of action. The current recommended dosing regimen is a 210-mg subcutaneous injection at weeks 0, 1, and 2, and every 2 weeks thereafte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yeung, Jensen, Ladda, Matthew, Piguet, Vincent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	JCMS Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011332/ https://www.ncbi.nlm.nih.gov/pubmed/32095245 http://dx.doi.org/10.1177/2050313X20905672

Ejemplares similares

Case of resolution of plaque psoriasis following treatment with rifampicin for latent tuberculosis: A case report
por: Muntyanu, Anastasiya, et al.
Publicado: (2023)

Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
por: Timmermann, Stine, et al.
Publicado: (2019)

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
por: Cacciapuoti, Sara, et al.
Publicado: (2023)

Plaque psoriasis and morphea in a patient on ustekinumab: A case report
por: Cirone, Katrina, et al.
Publicado: (2023)

Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review
por: Pinter, Andreas, et al.
Publicado: (2019)

Psoriasis appearing after dupilumab therapy in atopic dermatitis: A case report
por: Kim, Ho Seung, et al.
Publicado: (2020)

Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: A case report
por: Bose, Reetesh, et al.
Publicado: (2020)

Treatment of moderate to severe psoriasis with apremilast over 2 years in the context of long-term treated HIV infection: A case report
por: Zarbafian, Misha, et al.
Publicado: (2019)

Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy
por: Roman, Michael, et al.
Publicado: (2017)

Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
por: Lambert, Jo, et al.
Publicado: (2021)

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
por: Galluzzo, M, et al.
Publicado: (2019)

Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
por: Fargnoli, Maria Concetta, et al.
Publicado: (2023)

Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis
por: Coimbra, Susana, et al.
Publicado: (2014)

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
por: Hampton, Philip, et al.
Publicado: (2021)

A case report of psoriasis flare following immunotherapy: Report of an important entity and literature review
por: Politi, Anastasia, et al.
Publicado: (2020)

A case of rapid fingernail growth associated with nail psoriasis: A case report
por: Conway, Jade, et al.
Publicado: (2023)

Chronic annular pustular psoriasis resembling subcorneal pustular dermatosis: A case report
por: Khosravi-Hafshejani, Touraj, et al.
Publicado: (2019)

Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
por: REICH, Kristian, et al.
Publicado: (2022)

Brodalumab in the Treatment of Plaque Psoriasis Localized in Difficult-to-Treat Areas: A Narrative Review
por: Cannizzaro, Maria Vittoria, et al.
Publicado: (2023)

Palisaded neutrophilic and granulomatous dermatitis following a long-standing monoclonal gammopathy: A case report
por: Zabihi-pour, Dorsa, et al.
Publicado: (2021)

Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double‐blind, placebo‐controlled study
por: Seo, Seong Jun, et al.
Publicado: (2020)

Long‐term safety of brodalumab in Japanese patients with plaque psoriasis: An open‐label extension study
por: Yamaguchi, Yukie, et al.
Publicado: (2020)

Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics
por: Menter, Alan, et al.
Publicado: (2020)

Brodalumab in psoriasis: evidence to date and clinical potential
por: Foulkes, Amy C, et al.
Publicado: (2019)

Malignancy Rates in Brodalumab Clinical Studies for Psoriasis
por: Gottlieb, Alice, et al.
Publicado: (2020)

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
por: Lebwohl, Mark G., et al.
Publicado: (2019)

Adrenal Insufficiency Secondary to Abrupt Dose Reduction of Topical Corticosteroid Therapy after Starting Brodalumab for Psoriasis: A Case Report
por: Yamane, Mariko, et al.
Publicado: (2022)

Clinical potential of brodalumab in the management of psoriasis: the evidence to date
por: Sandoval, Laura F, et al.
Publicado: (2015)

Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States
por: Feldman, Steven R., et al.
Publicado: (2018)

Low-dose subcutaneous immunoglobulin is an effective treatment for autoimmune bullous skin disorders: A case report
por: Streu, Erin, et al.
Publicado: (2020)

Improvement in Hailey–Hailey disease with a combination of low-dose naltrexone and oral magnesium chloride: A case report
por: Lim, Darosa, et al.
Publicado: (2020)

The use of interleukin-23 inhibitors to treat immune-related psoriasis induced by immune checkpoint inhibitors and in patients with active cancer: A case series and review of the literature
por: Fournier, Cynthia, et al.
Publicado: (2023)

Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Protocol for the safety of brodalumab regarding psychiatric comorbidities in patients with psoriasis
por: Pikou, O., et al.
Publicado: (2022)

Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: A case report
por: Bourkas, Adrienn N, et al.
Publicado: (2022)

Variable response of post-Mohs surgery telangiectasias to KTP laser: A case report
por: Villeneuve-Tang, Catherine, et al.
Publicado: (2018)

Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Severe Psoriasis Successfully Treated with Brodalumab after Eradication of Hepatitis C Virus with Glecaprevir and Pibrentasvir: A Case Report
por: Ito, Michiko, et al.
Publicado: (2021)

A case of erythromelalgia with gastrointestinal dysautonomia treated with immunoglobulin: A case report
por: Bourkas, Adrienn N, et al.
Publicado: (2023)

A case of recalcitrant silicone granuloma treated with adalimumab: A case report
por: Silverberg, Orli M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gsbu4r59ikeh8mm6t2s6h53dpk